WanJiaYuan International Geriatric Hospital in Nanyang, China and MentisCura announce an agreement to implement MentisCura’s advanced electrophysiological analytic tools for the early detection and monitoring of Alzheimer’s disease and other dementias
REYKJAVIK, Iceland--(BUSINESS WIRE)-- MentisCura Diagnostics (www.mentiscura.com) and WanJiaYuan International Geriatric Hospital today announced the signing of an agreement to implement MentisCura’s proprietary diagnostic tools to improve care for patients with dementia and related CNS disorders.
Mentiscura’s EEG-based diagnostics will be part of a state-of-the art technology suite being deployed at the WanJiaYuan International Geriatric Hospital, expected to open in June 2014. The hospital, based in Nanyang in the Henan province, will be a 120,000 square meter, 1200 bed campus, one of the largest facilities of its kind in the world to focus solely on setting new standards of quality of managed care for the elderly, with at least 200 beds dedicated to dementia patients. WanJiaYuan International Geriatric Hospital also aims to establish a leadership position in geriatric research through the development of a center of excellence attracting over 100 international experts.
“We are honoured to be associated with a project that is of an unprecedented scale, even by international standards. The high-throughput and non-invasive nature of our electrophysiological analysis makes it uniquely useful in a real world clinical setting, where physicians need to assess patients and make care decisions before these diseases have reached a late and untreatable stage. From a five-minute standard EEG recording, our powerful analytical systems are able to provide immediate diagnostic output, offering genuine clinical benefit and scalability for even the largest facilities.” said Kristinn Gretarsson, CEO of MentisCura.
“Our hospital is committed to addressing the growing burden of care associated with diseases of ageing. We are delighted to be collaborating with MentisCura to use its innovative clinical technologies to guide earlier, lower cost diagnosis. We believe that biomarkers of disease will increasingly play an important role in our diagnostic protocol for dementia, as well as monitoring of disease progression and treatment efficacy,” commented Dr. Jin-Jing Pei, MD, Chief Physician at WanJiaYuan International Geriatric Hospital.
MentisCura offers a complete, integrated service to hospitals and general practitioners through sampling, processing and analysis of patient EEG data. The MentisCura Analysis System is a CE marked diagnostic aid, based on advanced, proprietary EEG-biomarker technology platform that accurately correlates changes in electrophysiology to specific disease pathologies, based on the company’s comprehensive proprietary EEG database for dementia and cognitive disorders. The platform supports diagnoses for most common types of dementia, including Alzheimer’s disease and Lewy body dementia.
MentisCura Diagnostics, based in Reykjavik, Iceland, is a privately held diagnostic company serving clinicians and pharmaceutical clients with state-of-the-art services and technology to improve and accelerate the differential diagnosis of CNS disorders. The company currently operates the world’s first fully automated EEG-based biomarker service for clinicians through its own clinic and remotely via electronically transmitted EEG recordings.
Founded in 2002 by Dr. Kristinn Johnsen, MentisCura’s service is based on a decade of design, development and clinical validation of powerful algorithm-based biomarkers by its team of clinical specialists and neurophysiological experts. From a five minute EEG recording, MentisCura provides a fast and reliable assessment of the likelihood that a patient is suffering from dementia and the type, including Alzheimer’s disease and Lewy body dementia.
The MentisCura Analysis System is a CE marked product to comply with the provisions of the European Medical Device Directive 93/42/EEC (MDD).
Source: MentisCura Diagnostics